Barrett Adenocarcinoma — Variants & evidence

Barrett Adenocarcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Amplification1
(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID470 In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial. PMID 20840671 · Marx et al., 2010 · Open in CIViC	civic

Data updated 22 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.